IDH1 and central nervous system neoplasm: The mutations in IDH1/2 represent also an independent and important GBM prognostic factor [12–16] and their routine assessment should be the standard in the clinical management of patients with gliomas (including GBM) according to the recently updated World Health Organization (WHO) 2016 classification of CNS tumors and European Association for Neuro-Oncology (EANO) guidelines on the diagnosis and treatment of glial tumors [17, 18].